A Phase 2 Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Randomized, double-blind, placebo-controlled, parallel-group, multi-center study followed by open-label phase. To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days